Caribou Biosciences, Inc. (CRBU) Dividend History

Caribou Biosciences, Inc. is a biotechnology company focused on developing gene-editing technologies using CRISPR-Cas3 and other CRISPR-based tools. Founded in 2011, it specializes in precision gene editing for applications in agriculture, human therapeutics, and industrial biotechnology. The company's platform aims to enable more efficient, accurate, and versatile genetic modifications to address various biological challenges.

2929 7th Street, Suite 105, Berkeley, CA, 94710
Phone: 510-982-6030
Website: https://www.cariboubio.com

Dividend History

Caribou Biosciences, Inc. currently does not pay dividends

Company News

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Caribou Biosciences, a clinical-stage CRISPR genome-editing biopharmaceutical company, announced a strategic pipeline prioritization with a focus on its CB-010 and CB-011 oncology programs. The company expects this move to extend its cash runway by one year into H2 2027.

GlobeNewswire Inc.
CRBU DEADLINE NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Caribou Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 24 Deadline in Securities Class Action – CRBU

Caribou Biosciences, Inc. is facing a securities class action lawsuit, and investors who purchased the company's securities between July 14, 2023 and July 16, 2024 may be eligible for compensation. The deadline to join the lawsuit is February 24, 2025.

GlobeNewswire Inc.
CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Caribou Biosciences, Inc. (CRBU) alleging the company made materially false and misleading statements about the safety, efficacy, and commercial prospects of its drug CB-010, as well as its financial position.

GlobeNewswire Inc.
CRBU IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important February 24 Deadline in Securities Class Action - CRBU

Caribou Biosciences, Inc. (CRBU) is facing a securities class action lawsuit, and the lead plaintiff deadline is February 24, 2025. The lawsuit alleges that the company made false and misleading statements about the safety, efficacy, and commercial prospects of its product CB-010.

GlobeNewswire Inc.
CRBU DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important February 24 Deadline in Securities Class Action - CRBU

Caribou Biosciences, Inc. is facing a securities class action lawsuit, with a February 24, 2025 deadline for investors to join the case. The lawsuit alleges that the company made false and misleading statements about the safety, efficacy, and commercial prospects of its CB-010 product.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 15:10:30 UTC